The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals has released the results of its LUGANO Phase 3 clinical trial, bringing renewed attention to treatment prospects for patients suffering from wet age-related macular degeneration (AMD).
Company Chief Strategic Science Officer Dr. Tarek Hassan detailed the outcomes during 'The Spotlight Series', highlighting key data insights and indicating anticipation for further advancements as the focus moves to the upcoming LUCIA trial. The company remains optimistic about its pipeline in retinal disease, aiming to deliver meaningful improvements for wet AMD patients.
View post on X Loading...
Eyepoint previously released topline results from its pivotal Phase 3 LUGANO trial of DURAVYU for wet AMD treatment, according to company disclosures. The company also reported promising LUGANO trial results for sustained release TKIs in wet AMD treatment in a separate update last year. The latest announcement continues a series of data releases focused on expanding retinal disease therapies.